Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer
Autor/innen
- S. Gupta
- I.A. Strohbehn
- Q. Wang
- P.E. Hanna
- R. Seethapathy
- J.M. Prosek
- S.M. Herrmann
- A. Abudayyeh
- A.B. Malik
- S. Loew
- C.A. Carlos
- W.T. Chang
- P. Beckerman
- Z. Mithani
- C.V. Shah
- A. Renaghan
- S. de Seigneux
- L. Campedel
- A. Kitchlu
- D.S. Shin
- G. Coppock
- N. Lumlertgul
- P. Garcia
- D.I. Ortiz-Melo
- A. Rashidi
- B. Sprangers
- V. Aggarwal
- K. Benesova
- K.D. Jhaveri
- F.B. Cortazar
- A. Weins
- Y. Zuo
- M.J. Mooradian
- K.L. Reynolds
- D.E. Leaf
- M.E. Sise
Quellenangabe
- Kidney Int 102 (4): 930-935
DOI
doi:10.1016/j.kint.2022.07.019
